Physician profile
Michael Busby
NPI 1962462671
$1,649.08
in general payments reported to CMS, 2019-2025
18 companies · $87.92 in 2025
The $87.92 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $296 · 2023: $277 · 2024: $274 · 2025: $87.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.80 | 2021-2024 | |
| Glaxosmithkline, LLC. | $239.74 | 2021-2025 | Trelegy Ellipta, Bexsero |
| Lilly USA, LLC | $191.52 | 2021-2024 | Jardiance, Mounjaro |
| Pfizer INC. | $140.69 | 2021-2023 | |
| Dexcom, INC. | $139.33 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.07 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $78.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.71 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $63.19 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $57.27 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $51.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $45.77 | 2023-2024 | Repatha |
| Astellas Pharma US INC | $39.66 | 2023 | Myrbetriq, Veozah |
| Abbott Laboratories | $32.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $30.48 | 2022-2023 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.13 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Busby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.